Patent ID: 7745690

Claim:
A transgenic mouse or rat whose genome comprises a foreign DNA, the foreign DNA comprising a type II collagen promoter, a MHC class II transactivator gene, and a type II collagen enhancer sequence, wherein said DNA is located under the control of said type II collagen promoter and enhancer, wherein administration of type II collagen to said transgenic mouse or rat at a dose of 0.01 mg to 0.05 mg two or more times results in presentation of pathologic conditions of human rheumatoid arthritis in said transgenic mouse or rat, wherein the pathologic conditions of human rheumatoid arthritis show the following pathologic conditions (1) to (6): (1) Joint swelling is observed in the whole body; (2) Joint swelling lasting for a week or more is observed; (3) Destruction, ankylosis, or deformity of bones in the extremities is observed; (4) Infiltration of lymphoid cells is observed; (5) Cartilage destruction and bone destruction due to formation of granulation tissue are observed; and (6) Joint deformity progresses through early stage (stage I) and moderate stage (stage II).